Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 GeneticVariation disease BEFREE Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene. 10356316 1999
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease CTD_human A recent study has shown mutations in CLN2 gene, that encodes a novel lysosomal pepstatin-insensitive proteinase (LPIP), in the pathophysiology of late-infantile neuronal ceroid lipofuscinosis (LINCL). 10320038 1999
Entrez Id: 54982
Gene Symbol: CLN6
CLN6
0.590 GeneticVariation disease BEFREE A survey of fibroblasts and lymphoblasts demonstrated that lack of activity was associated with LINCL arising from mutations in the CLN2 gene but not other neuronal ceroid lipofuscinoses (NCLs), including the CLN6 variant LINCL, classical infantile NCL, classical juvenile NCL, and adult NCL (Kufs' disease). 10428067 1999
Entrez Id: 54982
Gene Symbol: CLN6
CLN6
0.590 GeneticVariation disease BEFREE CLN6, the gene for a variant late infantile neuronal ceroid lipofuscinosis, has been mapped to chromosome 15q21-23 by homozygosity mapping. 10191123 1999
Entrez Id: 1201
Gene Symbol: CLN3
CLN3
0.540 Biomarker disease MGD Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. 10527801 1999
Entrez Id: 1201
Gene Symbol: CLN3
CLN3
0.540 Biomarker disease MGD A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). 10440905 1999
Entrez Id: 256471
Gene Symbol: MFSD8
MFSD8
0.370 GeneticVariation disease BEFREE A new locus for variant late infantile neuronal ceroid lipofuscinosis-CLN7. 10191125 1999
Entrez Id: 2055
Gene Symbol: CLN8
CLN8
0.240 Biomarker disease MGD An early-onset congenic strain of the motor neuron degeneration (mnd) mouse. 10191135 1999
Entrez Id: 1203
Gene Symbol: CLN5
CLN5
0.240 GeneticVariation disease BEFREE Prenatal diagnosis of variant late infantile neuronal ceroid lipofuscinosis (vLINCL[Finnish]; CLN5). 10419622 1999
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 GeneticVariation disease BEFREE We identified a novel nonsense CLN2 mutation (Q509X) in three Italian children with classical late-infantile neuronal ceroid lipofuscinosis (LINCL) from two unrelated families. 10862088 2000
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE Recently, the LINCL gene (CLN2) has been found to code for a pepstatin-insensitive lysosomal protease whose activity is deficient in LINCL specimens. 10665500 2000
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease BEFREE Exclusion of late infantile neuronal ceroid lipofuscinosis (LINCL) in a fetus by assay of tripeptidyl peptidase I in chorionic villi. 10740208 2000
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis. 10679303 2000
Entrez Id: 1509
Gene Symbol: CTSD
CTSD
0.200 Biomarker disease MGD Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. 10995834 2000
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease BEFREE Our laboratory has developed a diagnostic service for classical late infantile neuronal ceroid lipofuscinosis (LINCL) by assay of tripeptidyl-peptidase I (TPP-I) activity using the fluorogenic peptide substrate Ala-Ala-Phe aminomethylcoumarin, followed by a screen for three mutations in the CLN2 gene. 11588997 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE The expression of unequivocal TPP-I deficiency in CV demonstrates that enzyme assay is a reliable option for prenatal diagnosis of LINCL. 11241534 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease BEFREE An assay for the CLN2p/TPP-I based on the cleavage of amino terminal tripeptide from G-F-F-L-AFC was applied to prenatal and postnatal diagnosis of LINCL patients and heterozygote carriers. 11589010 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 GeneticVariation disease BEFREE Late-infantile neuronal ceroid lipofuscinosis (LINCL), an autosomal recessively inherited lysosomal storage disorder characterized by autofluorescent inclusions and rapid progression of neurodegeneration, is due to CLN2 gene mutations. 11339651 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE Of particular importance was the finding of normal TPP-I activity in two patients who had been diagnosed as having classical late infantile neuronal ceroid lipofuscinosis. 11588996 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 GeneticVariation disease BEFREE Association of the R447H mutation with a delayed onset form of LINCL in two separate families raised the question of whether R447H CLN2 retains residual activity. 11462245 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE Treatment of LINCL fibroblasts with recombinant CLN2 protein restores normal enzyme activity and ameliorates accumulation of the major storage protein, mitochondrial ATP synthase subunit c. 11415435 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease BEFREE Complementary molecular studies identified mutations in the CLN2 gene in the archival tissues and thereby convincingly demonstrated that these three children truly had classic late infantile neuronal ceroid lipofuscinosis (LINCL), now called CLN2. 11588998 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease BEFREE This observation suggests that the presence of small amounts of TPP-I in lysosomes is able to delay significantly CLN2 disease process. 11589013 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 AlteredExpression disease BEFREE The aim of this study was to examine the ability of the aminoglycoside gentamicin to restore TPP-I activity in LINCL cell lines. 11589009 2001
Entrez Id: 1200
Gene Symbol: TPP1
TPP1
0.800 Biomarker disease CTD_human The aim of this study was to examine the ability of the aminoglycoside gentamicin to restore TPP-I activity in LINCL cell lines. 11589009 2001